Foresite Capital Management Ii, LLC Aerie Pharmaceuticals Inc Transaction History

Foresite Capital Management Ii, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 13, 2020	SELL	$12.0 - $16.13 $3.04 Million - $4.09 Million	-253,698 Closed	0 $0
Q1 2020 May 14, 2020	SELL	$11.84 - $25.52 $16.8 Million - $36.2 Million	-1,419,016 Reduced 84.83%	253,698 $3.43 Million
Q4 2018 Feb 13, 2019	BUY	$33.0 - $60.04 $6.86 Million - $12.5 Million	207,965 Added 14.2%	1,672,714 $60.4 Million
Q2 2018 Aug 14, 2018	SELL	$47.85 - $70.45 $9.95 Million - $14.7 Million	-207,965 Reduced 12.43%	1,464,749 $98.9 Million
Q2 2017 Aug 14, 2017	BUY	N/A	1,672,714	1,672,714 $87.9 Million

2.4M

Ticker AERI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,390,500
Description
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...

Get notified when there are updates to the investment portfolio of Foresite Capital Management Ii, LLC, based on Form 13F filings with the SEC.

Stay updated on Foresite Capital Management Ii, LLC with notifications on news.